Adding chemotherapy doubled progression-free survival when EGFR and TP53 are both mutated

The edition in brief

Sixty-three observational studies covering 2,150,518 patients with laboratory-confirmed seasonal influenza were pooled for WHO. In non-severe influenza, cardiovascular disease (OR 2.72), immunosuppression (2.70), neurological disease (2.31) and chronic respiratory disease (2.24) were the major risks for hospital admission, with pregnancy, diabetes and malignancy adding further risk. In severe influenza, secondary bacterial infection (4.13), malnutrition (3.29), sepsis (3.19), acute kidney injury (2.92) and age 65 or over (2.47) were the major risks for death. A post hoc analysis of five COPD trials defined stability as no moderate or severe exacerbation and no worsening in COPD Assessment Test score or FEV1; 22 per cent achieved it on triple therapy at 52 weeks, and those stable at week 28 had a 45.7 per cent lower subsequent exacerbation risk and a 51.7 per cent lower risk of death. Across 102 studies and 34,013 adults with polysomnography-confirmed obstructive sleep apnoea, 55.4 per cent met criteria for metabolic syndrome. An international cohort of 307 patients managed on extracorporeal membrane oxygenation without invasive ventilation found strategy failure in 40.7 per cent of those started awake and 24.2 per cent of those extubated on support, and failure carried six to eight times the hazard of death at 90 days. In EGFR-mutated advanced non-small-cell lung cancer with concurrent TP53 mutation, adding chemotherapy to osimertinib extended median progression-free survival from 15.6 to 34.0 months (hazard ratio 0.44).